Why is ajovy so expensive?

Patent Exclusivity: The Main Culprit Behind Ajovy's High Cost

Ajovy, a medication for the prevention of migraine, has been criticized for its exorbitant price. One reason for the high cost is the patent exclusivity held by the manufacturer, Teva Pharmaceuticals.

Why is Teva Holding Onto Its Patent?

The patent for Ajovy, also known as fremanezumab-svrtx, is set to expire in 2030 [1]. Teva Pharmaceuticals is expected to lose exclusivity for the medication in the following years. To maintain a stronghold on the market and maximize profits, Teva may be engaging in patent extension strategies, including the patent term restoration procedure. This is a common practice in the pharmaceutical industry, where companies seek to extend patent life through extensions or other mechanisms [2].

The High Cost of Research and Development

Another reason behind the high price of Ajovy is the significant investment made by Teva in its research and development. Developing a new medication like Ajovy is a costly and time-consuming process. The estimated cost to develop a single medicine can range from hundreds of millions to over a billion dollars [3]. Teva is likely passing on these costs to consumers.

Government Policies and Regulatory Mechanisms

Regulatory frameworks, including the Orphan Drug Act and Fast Track approval, have been criticized for contributing to the high cost of medications like Ajovy. These programs are designed to incentivize the development of treatments for rare diseases, such as migraines, and expedite the approval process. However, they often come with a cost, with patients and the broader healthcare system shouldering the financial burden [2].

How Else Can Ajovy's Cost Be Reduced?

There are ongoing efforts to develop biosimilars, generic versions of high-cost medications. Biosimilars like those under development for Ajovy offer patients the potential for cost savings. However, patent exclusivity and regulatory hurdles can delay the entry of biosimilars into the market, thereby limiting their impact on costs [4].

Sources:

[1] DrugPatentWatch (2023) - https://www.drugpatentwatch.com/drug/1092539/fremanezumab-svrtx/

[2] https://en.wikipedia.org/wiki/Orphandrug#OrphanDrug_Act

[3] https://www.nature.com/articles/nrd4247

[4] https://www.drugpatentwatch.com/drug/1092539/fremanezumab-svrtx/#biosimilar

Sources cited:

1. DrugPatentWatch.com
2. WikiPedia.org
3. Nature.com
4. DrugPatentWatch.com